<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00049374</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000258058</org_study_id>
    <secondary_id>MSGCC-210421</secondary_id>
    <secondary_id>NCI-5824</secondary_id>
    <nct_id>NCT00049374</nct_id>
  </id_info>
  <brief_title>Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma</brief_title>
  <official_title>A Phase II Study Of Genasense In Combination With Thalidomide And Dexamethasone In Relapsed And Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Maryland Greenebaum Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <brief_summary>
    <textblock>
      RATIONALE: Thalidomide may slow the growth of cancer cells. Oblimersen may increase the&#xD;
      effectiveness of thalidomide and dexamethasone by making cancer cells more sensitive to the&#xD;
      drugs.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combining thalidomide and dexamethasone&#xD;
      with oblimersen in treating patients who have relapsed or refractory multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the clinical efficacy of oblimersen, thalidomide, and dexamethasone, in terms&#xD;
           of complete and partial response rates, in patients with relapsed or refractory multiple&#xD;
           myeloma.&#xD;
&#xD;
        -  Determine the time to progression and duration of response in patients treated with this&#xD;
           regimen.&#xD;
&#xD;
        -  Determine the toxicity of this regimen in these patients.&#xD;
&#xD;
        -  Correlate disease response (clinical outcome) with changes in Bcl-2 levels in patients&#xD;
           treated with this regimen.&#xD;
&#xD;
        -  Determine the disease-free and overall survival of patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: Patients receive induction therapy comprising oblimersen IV continuously on days&#xD;
      1-7, 22-28, and 43-49, oral dexamethasone on days 4-7, 25-28, and 46-49, and oral thalidomide&#xD;
      daily beginning on day 4. Treatment continues in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Patients with stable disease after induction therapy receive maintenance therapy comprising&#xD;
      oblimersen IV continuously on days 1-7, oral dexamethasone on days 4-7, and oral thalidomide&#xD;
      daily. Courses repeat every 35 days for up to 2 years in the absence of disease progression&#xD;
      or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed for 3 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 10-46 patients will be accrued for this study within 10 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2002</start_date>
  <completion_date type="Actual">January 2006</completion_date>
  <primary_completion_date type="Actual">January 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete and partial remission</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relationship between molecular and clinical outcomes</measure>
  </secondary_outcome>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>oblimersen sodium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thalidomide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically and clinically confirmed multiple myeloma&#xD;
&#xD;
               -  Relapsed and/or refractory after chemotherapy or transplantation&#xD;
&#xD;
                    -  Patients with prior allogeneic transplantation must not have evidence of&#xD;
                       active graft-vs-host disease requiring immune suppression&#xD;
&#xD;
          -  Measurable disease defined by quantitative immune globulin levels in serum and/or&#xD;
             urine and bone marrow plasmacytosis&#xD;
&#xD;
               -  Patients with nonsecretory disease are eligible provided at least 1 plasmacytoma&#xD;
                  lesion is accurately measurable by MRI or CT scan&#xD;
&#xD;
          -  No known CNS involvement&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2 OR&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,000/mm^3*&#xD;
&#xD;
          -  Platelet count at least 50,000/mm^3* NOTE: *Unless secondary to bone marrow&#xD;
             plasmacytosis (more than 80% involvement)&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin less than 2 times normal&#xD;
&#xD;
          -  AST/ALT no greater than 3 times upper limit of normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 2 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Seizures allowed if under adequate control&#xD;
&#xD;
          -  No severe skin reactions from prior thalidomide&#xD;
&#xD;
          -  No prior allergic reactions attributed to agents used in this study&#xD;
&#xD;
          -  No sensory or motor neuropathy grade II or greater&#xD;
&#xD;
          -  No other uncontrolled concurrent illness that would preclude study therapy&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No psychiatric illness or social situations that would preclude study compliance&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use 2 effective methods of contraception for 1 month before,&#xD;
             during, and for 1 month after study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  See Chemotherapy&#xD;
&#xD;
          -  At least 6 weeks since prior thalidomide&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No more than 4 prior chemotherapy regimens, including autologous and/or allogeneic&#xD;
             stem cell transplantation regimens&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and&#xD;
             recovered&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Concurrent continuous steroids allowed for chronic treatment of disorders other than&#xD;
             myeloma&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No prior oblimersen&#xD;
&#xD;
          -  No other concurrent anticancer therapies or investigational agents&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashraf Z. Badros, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Maryland Greenebaum Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Greenebaum Cancer Center at University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201-1592</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Comprehensive Cancer Center - Manhattan</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Badros AZ, Goloubeva O, Rapoport AP, Ratterree B, Gahres N, Meisenberg B, Takebe N, Heyman M, Zwiebel J, Streicher H, Gocke CD, Tomic D, Flaws JA, Zhang B, Fenton RG. Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients. J Clin Oncol. 2005 Jun 20;23(18):4089-99. Epub 2005 May 2.</citation>
    <PMID>15867202</PMID>
  </results_reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>November 12, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>October 15, 2019</last_update_submitted>
  <last_update_submitted_qc>October 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2019</last_update_posted>
  <responsible_party>
    <organization>UM Greenebaum Cancer Center</organization>
  </responsible_party>
  <keyword>refractory multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Oblimersen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

